Things You Need to Buy for Your Newborn

Baby Checklist: Things You Need to Buy for Your Newborn : Expecting your first baby is the biggest blessing and happiness in the world, but it is also one of the biggest challenges in life. While you’re thrilled to welcome your bundle of joy to this world, a million questions must be running through your head.

Am I going to have everything prepared in time, will we pick out the right clothes, did we forget to baby proof some part of the house – are just some of the worries that soon-to-be parents ask themselves. If you’re one of those parents and you’re not 100% certain you have everything ready for your little one, check out the following list. We have all the essentials listed to help you out and offer you peace of mind.

Clothes galore

Baby Clothes Galore
Baby Clothes Galore

While you’ve probably bought an array of different onesies and bodysuits, we’d like to mention that you’ll need different sizes ready too. Some babies grow much faster than others, and even from the day they’re born they don’t fit in the newborn babies’ clothes. That’s why you should have clothes for 2-3 months old babies ready, together with the pieces for newborns. When you go shopping for baby clothes, look for roomy, comfortable clothes and pick out bodysuits because they will make the baby feel comfortable and ready to both play and sleep in it. Shirts, leggings, fleece jackets, zip-up sweaters, easy-to-put-on sweatshirts and similar outer layers will be necessary too. Hats and mittens, leg warmers and booties will look adorable on a baby as well.

Baby Gear

Baby Gear
Baby Gear

When you need a transporter to take your baby outside and have the little one stay comfortable, you’ll need a quality stroller. A baby carrier will allow you to carry your baby around without having to worry whether the stroller will fit inside the bus, for example. It’s easier to transport your baby like that when you’re in a hurry, and you need both of your hands to be free. When picking out the right baby carrier, make sure you look for the one that you can easily wash and dry. Don’t forget a car seat to keep your baby safe at all times and to respect the safety regulations.

Bathing Supplies

Bathing Supplies
Bathing Supplies

A baby bathtub is the first on the list of bathing supplies. Make sure you look for baby soap and shampoos that are specially made for babies with no-tears formulas. You’ll want to make bathing one of the most enjoyable moments in your baby’s life.  Instead of using regular towels, make sure you offer your little one ultra-soft and absorbent baby towels that you can easily wrap the baby in. Washcloths can come in handy too, preventing your baby from sliding around the tub, or to wipe them off after eating. A bath thermometer and bath toys are also nice to have during bathtubs.

Diapering must-haves

Diapering must-haves
Diapering must-haves

From diapers to a diapering table, baby wipes and changing pad – these are just some of the essentials you’ll need to keep your bundle of joy dry and happy. Wipes, a diaper cream, and a backpack or a tote are other necessities you’ll need in your diaper bag and at home. Newborns need to be changed often, so you’ll want to keep skin irritations at bay with unscented wipes and diaper cream.

Sleeping Essentials

Sleeping Essentials
Sleeping Essentials

A crib and mattress are the first two sleeping essentials you need for the baby. You can also opt for a play yard or a bassinet in the first few months. Three to five fitted crib sheets will be enough to keep you going for months maybe even a couple of years. Get a few mattress pads as well to keep the bedding set complete. If you have a big house and you can’t hear your baby fussing or crying as they sleep in their room, make sure you get a baby monitor so you can quickly respond to every noise they make.

Feeding and breastfeeding necessities

Feeding and breastfeeding necessities
Feeding and breastfeeding necessities

Nursing or feeding pillows will make both you and the baby super comfortable during breastfeeding time. Forget about sore neck and shoulders, and have all the comfort you need as you bond with your precious baby during feeding sessions. Additionally, make sure you have bibs and burp cloths ready as well. Burp cloths will easily catch any spit-up or other baby fluids, and with bibs, you’ll protect baby’s clothes from catching too many stains. Have a few bottles ready too, because you never know whether you’ll be able to breastfeed at all. Bottle warmers and bottle sterilizers will also be nice to have around to make cleaning and feeding much easier.


Welcoming your firstborn baby can be a little scary, but you have nothing to worry about. You’ll offer your baby all the love you have and in case you need a little bit of help with choosing all the necessities – you have this list to help you around. Feel free to ask your parents and friends who already have kids about a few pointers, and you’ll be all set for the little one to be born.



Author :

Jasmine Anderson is a lifestyle and beauty blogger based in Australia. She is an incurable daydreamer, who finds inspiration in little, everyday moments. Spending time at her cozy home office with her two cats, writing her blog, is her favorite thing in the world.





Related Videos about Baby Checklist: Things You Need to Buy for Your Newborn :



Newborn Baby Shopping – The list of Items You Need to Buy




Basic Items You Need for your Newborn | Buy Before Birth




Baby Checklist: Things You Need to Buy for Your Newborn

when to start buying baby stuff during pregnancy, newborn baby shopping list with pictures, newborn baby needs checklist, most essential things a newborn baby needs, baby things to buy before birth with pictures, baby shopping list for first time moms, baby items list with pictures, list of things to buy when pregnant,

Source link

Bolgart community pools funds to buy the local pub

When it looked like last orders had finally been called at the 104-year-old Bolgart Hotel, the locals were having none of it.

They ordered another round, turned out their pockets and staked their claim on the grand old hotel with its sweeping verandas that had so steadfastly served their town, generation after generation.

A syndicate of 16 mostly local families pooled their money to buy the aging beauty — with dreams of breathing new life into the premises and ensuring the hub of their community was not lost.

With rural townships facing steady decline, the syndicate decided the pub was crucial to retaining young adults in Bolgart, offering employment and keeping community spirit alive in their tiny town, about 140 kilometres north-east of Perth.

Heart of the town

One of the syndicate partners, Bolgart-bred Dustin Michael, said it was vital to country communities to have a local pub.

“Without them, I don’t know where guys would hang out and talk about their feelings and all that new-age stuff that we’re supposed to talk about these days — the best way is over a beer.”

Licensee Craig Wilkins said there had already been overwhelming support by crowds of locals and visitors keen to show how much they valued the pub.

“People really need a socialising point — there are other places but the pub, if it’s going well, becomes a second home,” Mr Wilkins said.

Bolgart Hotel syndicate member Dustin Michael reckons a local pub is crucial to a country community.(ABC Midwest and Wheatbelt: Samille Mitchell)

Early days

The hotel was built in 1916 as one of only six state hotels constructed in Western Australia. But about the time it celebrated 100 years as a watering hole for locals and travellers alike, the then owners were looking to sell.

When no-one was interested in buying it, alarmed locals organised a crowdfunding campaign to try to rescue the building.

But their target fell short.

It wasn’t until the local syndicate was formed and pooled its money that the pub was saved.

“It’s really almost exactly the same as it was when it was first built, except we don’t have the fowl runs and the stables that were on the original plans,” Mr Wilkins said.

Persistent stories of ghosts meant the new owners had the building “de-ghosted” — a process which apparently revealed three ghosts had been residing at the premises but “were happy the place was doing well”.

A historical sepia-toned image of an old double-story country hotel.
The Bolgart State Hotel in 1935.(Supplied: State Library of WA)

Future dreams

Renovations are already underway, with longer-term plans for a new beer garden, a micro-brewery and a paddock-to-plate menu using local produce.

Syndicate co-director Paul Michael said both locals and visitors had already thrown their support behind the community-owned hotel.

“Just in the short period of time our syndicate — which is mostly locals — has owned it we’ve turned it around with enthusiasm,” Mr Michael said.

Source link

Looking to a buy a car? A national shortage means you’ll probably pay more

Car sales plummeted in the spring, causing shipment lots to overfill and forcing cargo ships to hold new vehicles at sea for weeks. And with few sales and facing state shutdown orders, auto manufacturers like Ford Motor and General Motors halted production lines.

It was starting to look like another automotive crisis.

But fast-forward to August, where monthly vehicle sales were nearly 1.4 million—matching pre-pandemic sales of February and almost double the 745,353 vehicle sales in April. That’s what you call a V-shaped recovery.

The rebound was so fast that new and used vehicles skipped right from oversupply to shortage—which is driving up prices. The average list price of new vehicles in August is $39,410, up $807 from May, according to While the average price in August for used vehicles is $21,843, up $920 from May.

“In the second quarter, every major auto manufacturer shut down production—for the first time since World War II—which led to inventory shortages that are still being felt today,” Jared Allen, vice president of communications of the National Automobile Dealers Association told Fortune. “On top of that, the shortage of new-vehicle inventory has pushed many buyers to the used-car market, where supply is also low. The result is a significant increase in prices for used vehicles, as well.”

The combination of an improved economy—and older Americans trying to avoid public transportation during the pandemic—is driving up sales at auto dealerships. And it’s pushed inventory numbers for new vehicles to an eight-year low, according to Wards Intelligence.

When will auto production catch back up?

“We expect this to be temporary … barring any unexpected parts delays or vehicle plant shutdowns stemming from new COVID-19 outbreaks, we expect that vehicle inventory levels will be at close to normal levels,” Allen says. Beyond cars, the economy at large is facing widespread shortages caused by the production shutdowns in the spring and resurgent demand in the summer. Everything from lumber, coins, ammo, beef, to medical supplies has been affected.

Shortages might bring higher prices for consumers, but on the flip side it means plenty of business for manufacturers.

More must-read finance coverage from Fortune:

Source link

Gilead nears deal to buy cancer drug maker for $20bn

Gilead Sciences is close to buying Immunomedics for $20bn, as the pharmaceutical group tries to outbid rivals competing to snap up the cancer drug developer, said people briefed on the matter.

Two people with direct knowledge of the matter warned that the transaction had not yet been definitively agreed and a rival bid could top Gilead’s. 

Gilead’s offer, worth close to double Immunomedics’ market value as of Friday, highlights the drugmaker’s willingness to overpay for takeover targets to secure new assets that can help replenish its portfolio of medicines and boost revenues.

Immunomedics, which is best known for its breast cancer drug Trodelvy, has been eyed by several large pharmaceutical groups in recent weeks, said two people with direct knowledge of the matter, as oncology therapies are some of the most sought after by large players in the sector. 

For Gilead this would be the third blockbuster oncology-focused deal in three years. The company, once the envy of the biotech world for its expensive cure for hepatitis C, which worked out at $1,000 per pill at one point, has been struggling amid greater competition.

Gilead has received renewed attention for remdesivir, a medicine that was once seen as a potential Ebola treatment and is still protected by patents, during the coronavirus pandemic. The drug received emergency approval for treating those who had fallen seriously ill from Covid-19. 

The California-based pharma’s renewed focus on oncology led it to acquire Kite Pharma for $12bn in 2017, adding a cutting edge cancer treatment to its portfolio. It also recently bought Forty Seven, a specialist in drugs that help the body’s own immune system combat a range of cancers, including leukaemia, for $5bn. 

If the deal goes through, Gilead will get access to antibody drug conjugates which aim to use the patient’s own immune system to fight cancer. It would follow in the footsteps of a recent deal between AstraZeneca and the Japanese pharmaceutical Daiichi Sankyo to develop and market an antibody drug conjugate called DS-1062 for lung and breast cancer.

Immunomedics reported a boost to its second-quarter earnings form Trodelvy, which received approval from US regulators in April. The New Jersey-based company said it had made $20.1m in net sales in the two months since the drug was approved. Shares in Immunomedics are up almost 100 per cent year to date. 

Gilead and Immunomedics did not immediately respond to a request for comment. 

The potential deal was first reported by The Wall Street Journal

Source link

Commonwealth Bank launches new no interest credit card to combat buy now, pay later

As young spenders turn their backs on high debt-accruing lending products, Commonwealth Bank has hastily launched a new no-interest credit card.

For a monthly fee ranging between $12 and $22, CBA’s new CommBank Neo card provides customers with a credit limit of up to $3000, attracting zero-interest, no annual or late fees and no foreign currency charges.

The new card offered by Australia’s largest retail bank, also gives customers a range of discounts and cash-back offers through CBA’s loyalty rewards program.

Retail banking executive Angus Sullivan said the card was a response to younger consumers having less of an appetite for traditional credit products, which could cause debts to blowout through high interest fees.

Traditional credit cards can attract annual interest rates anywhere between 10 per cent to nearly 25 per cent.

“It is a card to make payments,” Mr Sullivan said.

“This is far more expansive than the category label of credit cards.”

Camera IconCommonwealth Bank group executive of retail banking services Angus Sullivan. Credit: News Corp Australia, Chris Pavlich/The Australian

CBA’s latest payment product comes one day after rival bank NAB announced the first ever no-interest credit card in the Australian personal lending market.

The venture into no-interest incurring loans by both banks coincides with a boom in buy now, pay later lending platforms such as Afterpay and Zip, which are enabling consumers to purchase goods and services through instalment payments that do not incur interest fees.

‘This hybrid space provides much more flexibility to use and pay back over a time which is more convenient for them (consumers),” Mr Sullivan said.

“The buy now, pay later space is very constrained to four payments over a 55 day type of contract.”

NAB group executive for personal banking Rachel Slade said on Wednesday credit cards had not evolved with the growing shift towards debit spending.

NAB was the first to launch Australia’s first no-interest credit card.
Camera IconNAB was the first to launch Australia’s first no-interest credit card. Credit: Supplied

Both CBA and NAB’s new cards do not charge consumers monthly fees if the card is not in use for a respective month.

Mr Sullivan said the bank’s decision to offer cash-back rewards for shopping at certain merchants meant consumers were able to recoup the cost of the monthly fee.

The card’s minimum monthly repayment is $25, or 2 per cent of the closing balance, whichever is greater.

Monthly fees for the card are $12 for a $1000 limit, $18 for a $2000 limit and $22 for a $3000 limit.

ANZ and Westpac have not revealed whether they will offer no-interest credit cards.

Source link

Foran a good buy says Bulldogs NRL coach

Steve Georgallis says Brisbane should snap up unwanted playmaker Kieran Foran and that he would have if he was staying on as Canterbury coach.

Foran and the Bulldogs could not agree to terms with incoming coach Trent Barrett instead opting for another veteran in Blake Green to wear the No.6 jersey in 2021.

Georgallis, who took the reins at the Bulldogs after the departure of Dean Pay, is a Foran fan.

He said the Broncos would benefit from the experience of the Kiwi Test star, despite his long injury history which includes a torn pectoral muscle which ended Foran’s 2020 season

Georgallis said the latest setback in round 17 was an “impact injury” rather than a breakdown which has plagued Foran’s career, with the 30-year-old the standout in a tough season for the last-placed Bulldogs.

“I’ve worked with Kieran the last few years and I worked with him at Manly when I there and he’s a very experienced half, who plays the game at 100 miles an hour,” Georgallis said on Thursday.

“Players love playing with him and he’s the type of player the Broncos could do with, definitely.”

Georgallis won’t part of Barrett’s coaching staff so has no input on the playing list beyond this season, but said if he did he would snap up Foran who is expected to recover in time for round one 2021.

“Trent Barrett is coming to the club and he wants his roster for next year but, for me, I’d have Kieran in my team, but with a different coach coming in, he needs to have his team,” Georgallis said.

The Broncos are believed to be looking at Foran to play alongside their rookie halfback Tom Dearden next year, however, any new signings are on hold until the appointment of a fulltime coach to replace Anthony Seibold.

Source link

Macquarie pays $7 million to investor told to buy in company about to crash

Frawley was part of a cycling group based in Melbourne’s bayside suburbs with Macquarie investment adviser Stefan Whiting, who encouraged his friends and connections in the wealthy area to invest in the fledgling mining company.

Mr James and Frawley became clients of Mr Whiting and another Macquarie adviser, who urged them to buy shares in Cleveland Mining Group.

Former Macquarie adviser Stefan Whiting.Credit:Facebook

However, Frawley lost almost $100,000 investing in Cleveland and other speculative stocks, before abruptly ending his association with Mr Whiting. He was pursuing Macquarie for compensation at the time of his sudden death last year.

A Macquarie spokeswoman declined to comment on whether any settlement had been reached with Frawley’s estate, or discuss the resolution with Mr James, but released a short statement to The Sunday Age.

“We say publicly in our dispute resolution statement that when clients raise concerns with us we will listen and try to find common ground. Where appropriate, we will look to resolve matters through mediation, settlement offers or other forms of dispute resolution.”

The spokeswoman said Macquarie stood by its 2017 internal review of allegations regarding Cleveland, which exonerated the bank and its staff of any wrongdoing.

The two executives, Macquarie’s then divisional director Michael Rosenbaum and Mr Whiting, an investment adviser, featured in a previous confidential court settlement after they repeatedly drugged a colleague with valium and laxatives during a business trip to South America. The pair had spiked the drinks of a male colleague as they travelled across Brazil and Chile in 2011 to inspect gold mines owned by Cleveland.

Former Macquarie Bank investment advisers Stefan Whiting, left, and Michael Rosenbaum.

Former Macquarie Bank investment advisers Stefan Whiting, left, and Michael Rosenbaum.

Cleveland was founded in 2009 with an initial market capitalisation of just $20 million and first appointed Macquarie in 2010 to raise $4.64 million in funding for several offshore mining projects.

In 2011, Mr Whiting became directly involved in Cleveland’s acquisition of a Brazilian iron ore mine.

According to preliminary core samples, the mine known as Ferradura was expected to deliver more than 10 billion tonnes of iron ore, with an initial report valuing the tenement at $34 billion. Macquarie and its employees had nothing to do with the report or its blue-sky forecasts.

In the six months after Mr Whiting introduced the Ferradura project to Cleveland, Mr Rosenbaum and another Macquarie adviser made more than 20 trades in Cleveland in the names of companies registered to them or family members.

Cleveland announced to the Australian Stock Exchange in February 2012 it had signed a memorandum of understanding to purchase the Ferradura mine, which caused the company’s share price to almost triple between March and April of that year.

The ASX queried why the stock had surged from 54¢ on March 19 to 76¢ just four days later, but the company was unable to explain the frenzied buying.

Behind the scenes, Mr Rosenbaum regularly asked a Cleveland insider for information from the company’s share register about the identity of sellers. Any available stock was promptly purchased to avoid any downward pressure on the share price.


“Can we see who sold yesterday?” Mr Rosenbaum asked in an email on September 28, 2011. “Yep” was the immediate response.

In another email on November 15, 2011, Mr Rosenbaum tells his source at Cleveland: “40 cents, only three dollars to go.”

Almost a year later, on September 7, 2012, Mr Rosenbaum appeared to be still attempting to prop up the share price. “Cleaned out all selling, onward and up,” he said in an email.

When clients wanted to sell Cleveland stock, Mr Whiting often intervened and urged them to hold, or buy more.


In an email to a former friend, Mr Whiting offered to personally buy the man’s shares if he wanted to sell.

“We have spent the last two weeks in South America with the company and are completely comfortable with the CDG [Cleveland ASX code] story … If you want to sell or know anyone who does, ask them to call me and we will arrange to buy their stock,” Mr Whiting said in a message on October 25, 2012.

As hundreds of Melbourne investors sat on massive paper profits, the plan to get Cleveland to $1.20 unravelled in spectacular fashion.

Cleveland received confirmation that the initial core samples, which indicated bountiful reserves of iron ore at the Ferradura mine, were wrong.

Despite, this Mr Whiting instructed Mr James to continue buying Cleveland stock even as Mr Rosenbaum was instructing preferred clients, including family members, to sell.

Mr James heeded the advice.

As word leaked out that Cleveland had been sold a dud, its stock price crashed and small fortunes vanished.

By December 2012, the share price had plummeted back to around 30¢. The fall continued over the following years, finally closing at 7¢ when the company requested a suspension from the ASX in October 2016.

In February 2018, Mr James told members of the Senate’s Economics Reference Committee that Michael Rosenbaum had made a series of “unbelievable” admissions during a phone call on August 3, 2017.

“I said, ‘look I’ve got to get to the bottom of what happened’. [Mr Rosenbaum] said, ‘yeah I know I’ve done the wrong thing and I know ASIC are going to come after me. I’ve been doing it all my life. Trading off my father’s account illegally. I’ve been running stocks’,” Mr James said in his recollection of the call to the committee.

The committee was told that Mr Rosenbaum dumped stock held by relatives and friends when he found out “Cleveland was a worthless piece of shit”.

Mr James complained to regulator Australian Financial Complaints Authority about Macquarie’s conduct but the watchdog refused to investigate. His company has a separate court case against the regulator over this, and the terms of Macquarie’s $6 million settlement only became public when they were aired during a Supreme Court hearing on August 21 in that matter.

Mr Rosenbaum declined to make any comment when contacted by The Sunday Age. Mr Rosenbaum and Mr Whiting both left Macquarie in 2013.


Mr Whiting’s lawyer, David Grant from Logie-Smith Lanyon Lawyers, said his client denied any wrongdoing and had “no knowledge of the terms of, or reasons for, any confidential settlement made by Macquarie”.

“Allegations by Mr James relating to Mr Whiting were investigated by a Senate committee resulting in no adverse findings against Mr Whiting,” Mr Grant said before threatening legal action against The Sunday Age.

Mr James and his lawyer, Michael Hazell of Macpherson Kelley Lawyers, both declined to discuss the settlement.

Cleveland was delisted from the ASX in October last year – another alleged victim of what stockbrokers refer to as a “pump and dump”, where those pulling the reins make a fortune and ordinary punters get wiped out.

Get our Morning & Evening Edition newsletters

The most important news, analysis and insights delivered to your inbox at the start and end of each day. Sign up to The Sydney Morning Herald’s newsletter here, The Age’s newsletter here, Brisbane Timeshere and WAtoday‘s here.

Most Viewed in Business


Source link

Manchester City owners buy a stake in Troyes

City Football Group, which owns the English Premier League outfit Manchester City, has bought a majority share in the French second division club Esperance Sportive Troyes Aube Champagne (ESTAC).

The purchase of the shares owned by Daniel Masoni brings to 10 the number of clubs in CFG’s global stable.

Along with Manchester City and Troyes, CFG also owns New York City, Melbourne City, Yokohama F Marinos in Japan, Montevideo City Torque in Uruguay, Girona in Spain, Sichuan Jiuniu in China, Mumbai City in India and Lommel SK in Belgium.

CFG added that the French businessman Maxime Ray had acquired a minority stake and would be part of the Troyes board of directors.

While Manchester City finished second in the Premier League and reached the last eight of the Champions League last season, Troyes were fourth in Ligue 2 when the 2019/20 campaign was abandoned due to the coronavirus pandemic.

Ferran Soriano, chief executive of CFG, said: “We have had an interest in French football for some time and have long admired Troyes, so we are delighted to have completed the acquisition of our 10th club and have a permanent presence in France.

“At City Football Group, our objective remains to play beautiful football, identify and develop grassroots talent and have a permanent presence in the world’s football centres.”

Orginally published on RFI

Source link

Buy or pass? The pros and cons of investing in 9 upcoming tech IPOs from Palantir to Asana

No tech company from California’s famed startup basin, Silicon Valley, has gone public since last year. That could be because some high-profile 2019 Silicon Valley IPOs like Uber and Lyft flopped. But investors have short memories, and this week a half-dozen startups from the Valley filed to go public. About another half-dozen tech startups from other regions also announced their IPO plans this week.

Here are some key statistics and pros and cons investors may want to weigh vis-à-vis Palantir, Asana, Snowflake, and the rest of the upcoming class of late 2020 tech IPOs. Each company’s description includes a link to its S-1 filing. All financial data is from 2019 unless otherwise indicated.

Palantir Technologies

Symbol: PLTR
2019 revenue: $743 million
Revenue growth: 25%
Gross margin: 67%
Net loss: $580 million

Founded in 2003, Palantir created software to help defense and intelligence analysts sort through massive amounts of information to catch terrorists. It has since branched out to offer big-data analysis software to commercial and nondefense customers as well. Cofounder and CEO Alex Karp is moving the company’s headquarters to Denver and took shots at the culture of Silicon Valley in a letter accompanying the IPO filing. “We seem to share fewer and fewer of the technology sector’s values and commitments,” he wrote. The company is going public via a direct listing.

Pros: Palantir has become synonymous with uncovering fraud and wrongdoing, a need that is unlikely to diminish, given human nature. As the world becomes increasingly digital, there is ever more data for Palantir to analyze. It is on pace to hit $1 billion of annual revenue soon.

Cons: Palantir has been in business for almost two decades and isn’t profitable yet, with substantial expenses for research and development accounting for almost half of its revenue, though that dropped to less than one-third in the first half of 2020. It has also run into controversy about some of its clients such as ICE. Palantir is already valued at $20 billion by its VC backers.


Symbol: SANA
2019 revenue: $143 million
Revenue growth: 86%
Gross margin: 86%
Net loss: $119 million

Asana was founded in 2008 by former Facebook cofounder Dustin Moskovitz. Its subscription software helps workers communicate and coordinate projects, avoiding long chains of email. The company is going public via a direct listing.

Pros: The company already has 1.2 million paid users. Customers typically increase their use of the platform once they sign on. Asana’s dollar-based net retention rate, which measures how much customers spent in a quarter versus how much the same customers spent a year earlier, is over 120% for 2020.

Cons: There is a lot of competition for organizing knowledge-worker tasks, ranging from giants like Microsoft and Google to Slack and Smartsheet.

Corsair Gaming

Symbol: CRSR
2019 revenue: $1.1 billion
Revenue growth: 17%
Gross margin: 20%
Net loss: $8 million

Corsair sells personal computers and related peripherals for video gamers and other high-performance users. Founded in 1994, the company was bought for $525 million in 2017 by an investor group led by EagleTree Capital. The company is going public in a traditional underwritten IPO.

Pros: Spending on video games is booming during the pandemic, and Corsair is one of the top suppliers of high-end PCs desired by gamers. The company has been profitable in the first half of 2020 and will be using proceeds from the IPO to pay down debt, further bolstering its bottom line.

Cons: Selling PCs is a highly competitive business and subject to rapid technological change.


Symbol: SNOW
2019 revenue: $265 million (fiscal year ended Jan. 31, 2020)
Revenue growth: 174%
Gross margin: 56%
Net loss: $349 million

Founded in 2012 by former Oracle developers, Snowflake is seeking nothing less than to reinvent the database for the cloud-computing era. New CEO Frank Slootman has been rapidly bulking up its sales force. It is going public in a traditional underwritten IPO.

Pros: Snowflake has been one the fastest-growing apps in the world of business as it helps customers harness vast amounts of data in a speedier and cheaper way than older solutions. Its net revenue retention rate was 169% last year.

Cons: Slootman’s sales push has led to massive sales and marketing expenses that exceeded revenue last year (though not in the first half of 2020). Many other companies see the same opportunity, including the three major cloud providers, Amazon, Google, and Microsoft, plus Oracle itself. Snowflake’s software runs on the servers of the major cloud providers, so in a sense Snowflake is dependent on its top rivals.

Sumo Logic

Symbol: SUMO
2019 revenue: $155 million (fiscal year ended Jan. 31, 2020)
Revenue growth: 50%
Gross margin: 71%
Net loss: $92 million

The 10-year-old cloud service seeks to help businesses monitor key metrics and real-time information for everything from customer sales to cybersecurity intrusions. It says it monitors 19 billion events per second for its customers. Sumo Logic is going public through a traditional IPO.

Pros: The growing trends of smart machines, or the Internet of things, and the use of artificial intelligence and machine-learning apps mean Sumo Logic should remain in high demand from a growing customer base.

Cons: There is plenty of competition to harness IoT and A.I. for businesses from rivals ranging from Splunk, Elastic, and Datadog to Amazon and Microsoft.

Unity Software

Symbol: U
2019 revenue: $542 million
Revenue growth: 42%
Gross margin: 78%
Net loss: $163 million

Unity, founded in 2004, provides the software underpinnings for many popular real-time and mobile video games, including Township, Monument Valley, and Oddworld. The company says 53% of the top 1,000 games on Apple and Google’s mobile app stores use its software. The company is planning a traditional IPO.

Pros: Mobile gaming remains a fast-growing market, and Unity is expanding into other fields like virtual reality experiences. Epic Games, a competitor, has recently put its reputation at risk by suing Apple.

Cons: In business for 16 years, Unity is still losing money. As rival Epic has discovered, Apple and Google can set onerous terms for game developers on their dominant mobile platforms.

Bentley Systems

Symbol: BSY
2019 revenue: $737 million
Revenue growth: 6%
Gross margin: 80%
Net income: $103 million

Bentley Systems is a leading software developer for the design, construction, and operation of big infrastructure projects like stadiums, dams, and airports. It was founded by the Bentley brothers—Barry, Keith, Ray, and Greg—in 1984. German conglomerate Siemens also owns a stake in the company. Bentley is doing a traditional IPO.

Pros: The company is a market leader for big construction project software and has allied with Siemens and Microsoft. For the past year, Bentley’s recurring revenue net retention rate was 110%. The company is profitable and has been for years.

Cons: Infrastructure construction is dependent on strong economic times. The company’s revenue has not grown much in the past few years. All of the shares being sold are from existing shareholders, so the company won’t get money to expand.


Symbol: AMWL
2019 revenue: $149 million
Revenue growth: 31%
Gross margin: 54%
Net loss: $88 million

Also known as American Well, the 14-year-old startup is a leader in the field of telehealth, helping connect doctors and nurses to patients via its software platform. The COVID-19 pandemic has created a boom time for Amwell: Of the 5.6 million telehealth visits it has hosted since going into business, 2.9 million, or 52%, were in the first half of this year. Google is an investor in the company, which is doing a traditional IPO.

Pros: As noted, the pandemic is prompting a massive shift to virtual health care visits that is expected to continue even after COVID-19 fades. The company has relationships with 150 top health systems, including over 2,000 hospitals.

Cons: The company has large losses relative to its revenue despite its long track record. Health care is also a highly regulated business, and restrictions on the use of telehealth, some of which were relaxed during the pandemic, could be tightened.


Symbol: FROG
2019 revenue: $105 million
Revenue growth: 65%
Gross margin: 81%
Net loss: $5 million

The Israeli company, founded in 2008, provides software to help programmers update and maintain their products. The company is doing a traditional IPO.

Pros: The company is almost profitable, reporting a loss of less than $500,000 for the first half of 2020. Its net revenue retention rate was 139%.

Cons: The style of software development that JFrog supports is not the way most developers release programs today and may not catch on.

More must-read finance coverage from Fortune:

Source link

Despite Another Pullback, This Analyst Says ‘Buy’

NVAX), with shares currently sitting well below its 52-week high.   ” data-reactid=”12″>My, how times have changed. Since soaring on promising Phase 1 data for its COVID-19 vaccine, NVX-CoV2373, that reaffirmed the best-in-class immunogenicity and reactogenicity profile, the waters have been choppy for Novavax (NVAX), with shares currently sitting well below its 52-week high.   

Mayank Mamtani, of B.Riley FBR, believes the recent weakness presents investors with a unique buying opportunity.” data-reactid=”13″>That said, 5-star analyst Mayank Mamtani, of B.Riley FBR, believes the recent weakness presents investors with a unique buying opportunity.

“We argue against the prevailing bearish sentiment on NVAX potentially falling behind in the second wave of COVID-19 vaccine candidates given the Phase 3 initiation timeline in early October, which might follow a surprise pre-Phase 3 Emergency Use Authorization (EUA) of the AstraZeneca’s vaccine candidate, AZD1222, and notably, around the timeline of Phase 3 efficacy readout from two mRNA candidates, Moderna’s mRNA-1273 and Pfizer/BioNTech’s BNT162b2,” Mamtani explained.

It should be noted that regardless of what the Phase 3 outcomes are for MRNA’s and PFE/BNTX’s vaccines, which are expected in September or October, Mamtani argues NVAX stands to benefit.

According to Mamtani, premature EUA authorization of AZD1222 before large randomized clinical efficacy trials are completed goes against the FDA’s statements that this path “could reduce the ability to demonstrate effectiveness of the investigational vaccine in a clinical disease endpoint efficacy trial to support licensure and such clinical disease endpoint efficacy trials may be needed to investigate the potential for vaccine-associated ERD.”

NVAX hasn’t jumped the gun when it comes to its Phase 3 study. Rather, the company conducted two Phase 2 studies to generate sufficient “manufacturing information and demonstrate the safety and effectiveness of ‘2373, which the agency may consider being more appropriate to receive EAU before the FDA has completed its formal review of the BLA,” in Mamtani’s opinion.

Looking more closely at NVAX’s Phase 2 program, which is being conducted across two different studies, the B.Riley FBR analyst likes its “breadth.” He added, “Based on the robust antibody responses, as well as the promising safety and tolerability profile generated in the Phase 1 portion of the Phase 1/2 study, two dose levels…will be evaluated. This, coupled with the previously announced Phase 2 2.9k-subject South Africa study and the 130-subject Phase 1 study, will generate a total of ~4.5K safety and efficacy dataset, well above the safety database of 3k study participants required by the FDA for pre-licensure.”

click here)” data-reactid=”23″>With the slew of data releases set to continue, beginning with an NEJM peer-reviewed publication of NVAX’s Phase 1 data and followed by immunogenicity and tolerability data in older adults in a few weeks, the deal is sealed for Mamtani. To this end, he maintains a Buy rating and $257 price target, suggesting 124% upside potential from current levels. (To watch Mamtani’s track record, click here)

See Novavax stock analysis on TipRanks)” data-reactid=”24″>Turning now to the rest of the Street, 4 Buys and 1 Sell have been published in the last three months, which add up to a Moderate Buy consensus rating. Given the $227.60 average price target, the upside potential lands at 112%. (See Novavax stock analysis on TipRanks)

Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.” data-reactid=”33″>To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

article was originally posted on TipRanks.” data-reactid=”35″>This article was originally posted on TipRanks.

Source link